C
Chengdu Pukang Weixin Biotechnology
Specializing in polypeptide drug side chains and PEG derivatives
About Chengdu Pukang Weixin Biotechnology
Chengdu Pukang Weixin Biotechnology Co., Ltd., also referred to as Pukang Bio, is a biopharmaceutical manufacturer established in 2008. The company specializes in the research, development, production, and sale of polypeptide long-acting drug side chains and single-molecule polyethylene glycol (PEG) derivatives. Pukang Bio operates as a Contract Development and Manufacturing Organization (CDMO), providing services to healthcare and pharmaceutical companies worldwide, with sales markets in East Asia, Europe, North America, and South Asia.
The company has developed a polypeptide long-acting modifier platform that supplies various peptide side chain molecules and offers design, research, and documentation services. These products, including aliphatic alkane, MIPA, and cholesterol series, are utilized in drugs for conditions like GLP-1 and HIV to extend their half-life and improve patient compliance. Pukang Bio has also built an extensive library of small-molecule PEG derivative blocks, which are used in biomedical applications such as drug delivery, ADC conjugation, and to enhance the stability of nucleic acid drugs like siRNA. Its product portfolio includes advanced intermediates, excipients, LINKERs, and various amino acids and their derivatives.
Pukang Bio is a privately held, venture capital-backed company. It has secured multiple funding rounds, including a Series B in October 2023 and a Series B1 in June 2024, with investors such as IDG Capital, GL Ventures, and Mirae Asset Global Investments. To support its operations, the company has a 3,000-square-meter R&D center, a pilot-scale laboratory, and a 60,000-square-meter production base that complies with GMP standards.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 13.7/100
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jun 2024 | $28M | $110M | IDG Capital · Hillhouse Capital · Mirae Asset Venture Investment · Huimei Technology | ↗ |
Growth signals
Latest recorded traffic for Chengdu Pukang Weixin Biotechnology is 410 monthly website visits.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Chengdu Pukang Weixin Biotechnology in its local ecosystem
The Chengdu Pukang Weixin Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
IDG Capital
Hillhouse Capital
Mirae Asset Venture Investment
Huimei Technology
Huatai Zijin Investment
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Chengdu Pukang Weixin Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Chengdu Pukang Weixin Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.